Inotiv (STU:BS50) Total Current Assets : €166.2 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Inotiv Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Inotiv's total current assets for the quarter that ended in Mar. 2024 was €166.2 Mil.

Inotiv Total Current Assets Historical Data

The historical data trend for Inotiv's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Total Current Assets Chart

Inotiv Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Current Assets

Get a 7-Day Free Trial

11.28

12.99

160.67

235.31

200.33

Inotiv Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															196.74	187.50	200.33	174.86	166.23

Inotiv Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Inotiv's Total Current Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	33.256	+	84.725	+	52.568	+	29.784
	=	200.3

Inotiv's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	30.079	+	63.852	+	41.774	+	30.52
	=	166.2

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Inotiv (STU:BS50) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Inotiv's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	30.079	-	559.559	+	0.75 * 50.619	+	0.5 * 41.774
=	-470.6

Inotiv Total Current Assets Related Terms

Thank you for viewing the detailed overview of Inotiv's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv (STU:BS50) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » Total Current Assets

Comparable Companies

STIM FONR BNR ACRS PRPH VNRX MDXH BDSX BIOQ PSNL TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

NOTV:USA

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines